Benzinga | Jun 15, 2021 08:06AM EDT

Cyclo Therapeutics Highlights Launch Of New Website

- Company dedicated to developing life-changing medicines through science and innovation for patients and families living with challenging diseases

- Pivotal Phase 3 study of Trappsol(r) Cyclo(tm) for Niemann-Pick Disease Type C (NPC) on track to commence site activation to begin enrollment this month

- Company advancing Alzheimer's Disease Phase 2 asset towards investigational new drug application (IND) filing anticipated in H2 2021

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced the launch of its new corporate website, cyclotherapeutics.com.